InvestorsObserver
×
News Home

Should Biotechnology Stock CytoDyn Inc (CYDY) Be in Your Portfolio Monday?

Monday, August 08, 2022 01:57 PM | InvestorsObserver Analysts

Mentioned in this article

Should Biotechnology Stock CytoDyn Inc (CYDY) Be in Your Portfolio Monday?

CytoDyn Inc (CYDY) is near the top in its industry group according to InvestorsObserver. CYDY gets an overall rating of 65. That means it scores higher than 65 percent of stocks. CytoDyn Inc gets a 71 rank in the Biotechnology industry. Biotechnology is number 27 out of 148 industries.

Overall Score - 65
CYDY has an Overall Score of 65. Find out what this means to you and get the rest of the rankings on CYDY!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With CytoDyn Inc Stock Today?

CytoDyn Inc (CYDY) stock is down -14.92% while the S&P 500 is up 0.09% as of 1:33 PM on Monday, Aug 8. CYDY is down -$0.17 from the previous closing price of $1.14 on volume of 4,179,583 shares. Over the past year the S&P 500 is lower by -6.39% while CYDY is down -30.71%. CYDY lost -$0.23 per share the over the last 12 months. Click Here to get the full Stock Report for CytoDyn Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App